Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
This randomized clinical trial evaluates the efficacy of sugemalimab plus capecitabine and oxaliplatin (CAPOX) vs placebo plus CAPOX as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with programmed death-ligand 1 combined positive score of 5 or greater.
This randomized clinical trial evaluates the efficacy of sugemalimab plus capecitabine and oxaliplatin (CAPOX) vs placebo plus CAPOX as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with programmed death-ligand 1 combined positive score of 5 or greater.
